I'd echo that. One of the main issues here is that ADR reporting is one signal. It's a challenge sometimes to detect those rare occurrences and connect the dots. It's the reason why post-market surveillance and post-market drug safety and effectiveness have to be monitored and evaluated by using a variety of tools, not the least of which is ADR reporting, but also administrative data analyses, and running brand-new trials and other mechanisms.
